Meloxep (Meloxicam)

Meloxep (meloxicam) is used to treat inflammatory and painful conditions affecting the musculoskeletal system.

• Osteoarthritis: reduces joint pain and improves functional mobility.
• Rheumatoid arthritis: alleviates inflammation and joint swelling, helping preserve joint function.
• Ankylosing spondylitis: diminishes spinal inflammation and associated pain.
• Acute pain: provides short‑term relief of moderate to severe pain from injuries or postoperative settings.

• Meloxicam preferentially inhibits cyclooxygenase‑2 (COX‑2) enzymes, decreasing the conversion of arachidonic acid to prostaglandins that mediate inflammation, pain and fever. By sparing COX‑1 activity, it aims to maintain gastric mucosal protection while delivering anti‑inflammatory and analgesic effects. This selective COX‑2 inhibition contributes to a favorable gastrointestinal safety profile compared with non‑selective NSAIDs.

Meloxep may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo: transient sensations of imbalance.
• Edema: peripheral swelling, often of the ankles.
• Elevated blood pressure: mild increases in systolic or diastolic pressure.
• Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding: potentially life‑threatening hemorrhage.
• Cardiovascular events: myocardial infarction, stroke or worsening heart failure.
• Renal impairment: acute kidney injury or reduced renal function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: hepatitis or elevated liver enzymes.
• Anaphylaxis: acute allergic reaction with respiratory compromise.

Before prescribing Meloxep, clinicians should evaluate patient risk factors and follow safety recommendations.

• Assess gastrointestinal risk: avoid in patients with active ulcers or a history of GI bleeding.
• Monitor renal function: use caution in those with impaired kidney function or dehydration.
• Evaluate cardiovascular status: consider risk of thrombotic events in patients with existing heart disease.
• Use lowest effective dose: limit duration to the shortest period necessary for symptom control.
• Check for hypersensitivity: discontinue if allergic reactions such as rash or bronchospasm occur.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Meloxep can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• Other NSAIDs or aspirin: additive gastrointestinal toxicity.
• ACE inhibitors or ARBs: may reduce renal perfusion and cause kidney injury.
• Diuretics: heightened risk of renal impairment and electrolyte disturbances.
• Lithium: elevated lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs): modestly increased bleeding risk.
• Corticosteroids: enhanced gastrointestinal ulcer risk.
• Cyclosporine: possible increase in nephrotoxicity.
• Digoxin: may raise serum digoxin concentrations.
• Methotrexate: reduced clearance, raising toxicity potential.